Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Ulcerative Colitis
NCT02058524Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in ulcerative colitis (UC), sponsored by University of Chicago. Primary endpoint: Comparison of microbiome pre and post transplant at 12 weeks. Started Jun 2013; status: terminated.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02058524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058524.